This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Not applicable	A study in cell culture suggests a conjugate prodrug of cisplatin and aspirin could be useful for reducing inflammation associated with chemotherapy. In one cultured human prostate cancer cell line, the conjugate increased apoptosis compared with a nonconjugated combination of the two compounds. In cultured macrophages, the conjugate decreased production of the proinflammatory cytokines IL-6 and tumor necrosis factor-α (TNF-α) and increased levels of the anti-inflammatory cytokine IL-10 compared with the nonconjugated combination. Next steps include optimization and preclinical testing in animal models of cancer. *SciBX* 7(9); doi:10.1038/scibx.2014.250 Published online March 6, 2014	Patent pending; licensed to Partikula LLC	Pathak, R.K. *et al. Angew. Chem. Int. Ed.*; published online Jan. 22, 2014; doi:10.1002/anie.201308899 **Contact:** Shanta Dhar, The University of Georgia, Athens, Ga. e-mail: shanta@uga.edu